Brazilian crypto exchange Mercado Bitcoin temporarily suspended deposits and withdrawals on November 2 after detecting a security incident in one of its systems. The exchange confirmed no customer funds were lost and no data breach occurred, but did not specify which system was affected or if any assets were stolen. Security teams are investigating the incident and coordinating with authorities, while the suspension remains a precautionary measure to protect users. The exchange has not announced when normal operations will resume amid ongoing investigations.
Mercado Bitcoin's security incident is context for readers following crypto markets. For readers following major cryptocurrencies on Pluang, as of Nov 02, 2026 20:43 WIB, 8 of 50 major cryptos rose and 41 fell. Notable movers include THETA at Rp2.779 (-3.94%), YFI at Rp35.420.568 (-3.75%), and CAKE at Rp34.506 (-3.64%).
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
